Workflow
泰康国证公共卫生与医疗健康交易型开放式指数证券投资基金
icon
Search documents
医疗健康ETF泰康: 泰康国证公共卫生与医疗健康交易型开放式指数证券投资基金2025年中期报告
Zheng Quan Zhi Xing· 2025-08-27 09:43
Fund Overview - The fund is named "TaiKang National Public Health and Medical Health Exchange-Traded Open-Ended Index Securities Investment Fund" and is managed by TaiKang Fund Management Co., Ltd. [2] - The fund's main code is 159760, and it was established on December 6, 2021, with trading commencing on December 20, 2021 [2]. - The fund aims to closely track the performance of its benchmark index, the National Public Health and Health Index, with a goal of minimizing tracking deviation and error [2][3]. Financial Performance - As of June 30, 2025, the fund's total net asset value was approximately 80.06 million RMB, with a net asset value per share of 0.5871 RMB [3][19]. - The fund reported a realized loss of approximately 11.16 million RMB for the period, with a profit of 1.25 million RMB [3][19]. - The weighted average net profit rate for the period was 1.50%, and the net value growth rate was 1.63% [3][19]. Investment Strategy - The fund primarily employs a full replication strategy to construct its stock investment portfolio based on the composition and weight of the benchmark index [2][11]. - The fund may also invest in fixed-income instruments to ensure liquidity and enhance investment returns [2][11]. - The fund's investment strategy includes hedging through stock index futures to improve investment efficiency while controlling risks [2][11]. Market Context - The macroeconomic environment in the first half of 2025 showed structural differentiation, with resilience in certain sectors like exports and manufacturing, while real estate cooled down after an initial recovery [10][14]. - The overall equity market experienced fluctuations, with the Shanghai Composite Index rising by 2.76% and the Hang Seng Index increasing by 20.18% during the same period [10][14]. - The pharmaceutical sector is expected to benefit from a series of policy incentives aimed at supporting the development of innovative drugs, marking a significant opportunity for investment in this area [14][10]. Management and Compliance - TaiKang Fund Management Co., Ltd. has been compliant with relevant laws and regulations, ensuring fair treatment of all funds under its management [9][10]. - The fund management has established a fair trading system and monitoring processes to prevent any conflicts of interest [9][10]. - The fund's valuation process is overseen by a dedicated valuation team, ensuring transparency and adherence to regulatory standards [14][15].